LEN vs TXG · rev $34.19B vs rev $610.8M
LEN (LEN) versus 10X Genomics Inc (TXG) — a side-by-side from cached financials, not a winner call.
LEN (LEN) common stock.
10X Genomics Inc (TXG) is a health information services company listed on NASDAQ.
Latest reported LEN revenue for 2025-11-30 was $34.19B. Net income was $2.08B. Revenue was down 3.5% from 2024-11-30 to 2025-11-30. LEN currently screens at market cap $0.
Latest reported TXG revenue for 2024-12-31 was $610.8M. Net income was -$182.6M. Revenue was down 1.3% from 2023-12-31 to 2024-12-31. TXG currently screens at market cap $4.08B.
LEN currently screens at market cap $0. TXG currently screens at market cap $4.08B.
Not investment advice. Open the LEN and TXG stock pages for the full models.
Not investment advice.